Targeting phospholipid metabolism for glioblastoma therapy

Affiliations

¹ The Ken & Ruth Davee Department of Neurology, Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Editorial

Tianzhi Huang et al. Neuro Oncol. 2021.

. 2021 Mar 25;23(3):343-344.

doi: 10.1093/neuonc/noaa309.

¹ The Ken & Ruth Davee Department of Neurology, Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

No abstract available

Comment on

PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
Yi K, Zhan Q, Wang Q, Tan Y, Fang C, Wang Y, Zhou J, Yang C, Li Y, Kang C. Yi K, et al. Neuro Oncol. 2021 Mar 25;23(3):387-399. doi: 10.1093/neuonc/noaa255. Neuro Oncol. 2021. PMID: 33140095 Free PMC article.

1. Kang YP, Ward NP, DeNicola GM. Recent advances in cancer metabolism: a technological perspective. Exp Mol Med. 2018;50(4):31. - PMC - PubMed
1. Cheng M, Bhujwalla ZM, Glunde K. Targeting phospholipid metabolism in cancer. Front Oncol. 2016;6:266. - PMC - PubMed
1. Yi K, Zhan Q, Wang Q, et al. . PTRF/Cavin1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2. Neuro Oncol. 2021;23(3):387–399. - PMC - PubMed
1. Huang K, Fang C, Yi K, et al. . The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes. Theranostics. 2018;8(6):1540–1557. - PMC - PubMed
1. Paulitschke V, Eichhoff O, Gerner C, et al. . Proteomic identification of a marker signature for MAPKi resistance in melanoma. EMBO J. 2019;38(15):e95874. - PMC - PubMed